PrEP

Dolutegravir/abacavir shows a solid safety profile and a high barrier to resistance.

Researchers examine strategies to control the spread of HIV.

Broad-spectrum HIV-targeting monoclonal antibodies may lead to a cure for HIV in the future.

Evidence-based treatment for depression and adherence counseling could boost HIV treatment.

HIV compromises the immune system, making patients more susceptible to tuberculosis.

Limited evidence connects HIV severity and highly active antiretroviral therapy (HAART) regimens.

Large proportion of adolescents who are HIV-positive are unaware of their infection.

HIV-infected patients may have worse outcomes in ocular syphilis than those without the virus.

Generic abacavir and lamivudine (Epzicom) tablets are indicated for the treatment of HIV-1 infection in combination with other antiretroviral medicines.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed effective techniques to boost HIV drug adherence.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.

Many patients wait until after becoming infected with HIV to seek treatment.

Patients with HIV previously believed to face an increased risk of cardiovascular disease.

Attacking dormant HIV cells shows promise eradicating disease.

Less than 10% of young gay, bisexual, and other men who have sex with men have used HIV pre-exposure prophylaxis.

HIV Test-and-Treat initiates antiretroviral therapy promptly, but may be too expensive to employ nationwide.

Transmission rates reduced 96% among couples who both received treatment.

Resistance development has been minimal under the controlled high adherence conditions of clinical trials. However, real-world adherence is less consistent.

Treatment with Truvada highly effective in reducing the risk of HIV.

Adherence to oral PrEP combined with coordinated counseling found to improve HIV therapy.

New study results suggest tenofovir rectal gel is a safe method for preventing HIV transmission.

HIV infection rate among gay and bisexual men remains a problem.

Tenofovir disoproxil fumarate and emtricitabine administered via a sustained release intravaginal ring shows promise treating (S)HIV.

Novel prevention methods can help reduce the 45,000 new cases of HIV that occur in the United States annually.